Bruker (NASDAQ:BRKR) Q4 Revenue Flat, Beats Estimates as Guidance Misses

Bruker (NASDAQ:BRKR) reported Q4 CY2025 revenue of $977.2 million, flat year-on-year and 1.4% above Wall Street estimates. The company raised full-year revenue guidance to $3.59B at the midpoint, 3.1% above consensus. Non-GAAP EPS of $0.59 missed by 10.9% but represents a 6.3% CAGR over five years. Supporting context: Organic revenue over the past two years was flat, suggesting growth was partly driven by acquisitions and foreign exchange. Operating margin for Q4 was 7.8%, down from 10.9% average over five years, reflecting higher expenses and pricing pressure. EPS growth lagged revenue expansion, with adjusted EPS down from $0.76 in Q4 2024. Analysts project 1.5% CAGR for revenue and 16.7% full-year EPS growth through 2026. The stock closed flat at $42.38 after the report, with guidance likely to weigh on near-term sentiment. Long-term performance remains mixed, with a 11.6% CAGR in revenue over five years outpaced by a steeper decline in operating margins.